

STUDY	ISSUE	CONTRACTING GOV. IDENTIFIER	SPONSORS AND COLLABORATORS	START DATE	STUDY COMPLETION DATE	FIRST POSTED	LAST UPDATED	INVESTIGATORS	CONTACTS	LINK
Basic Science Mechanism of Action	To understand the cellular and molecular mechanisms of disease severity in hospitalized patients with COVID-19, we conducted a multi-center observational study to determine the role of ACE2 in disease severity in hospitalized patients with COVID-19. (NIH R01-HL138501)	NCT04373232	Direct Biologics, LLC	Jan-23	Jan-23	19-Mar-21	16-Sep-21	Wenbin Song, MD Direct Biologics wensong@directbiologics.com	Wenbin Song Wenbin.Song@directbiologics.com 800-761-1021	https://www.clinicaltrials.gov/ct2/show/study/NCT04373232
Protective Effect of Statins in COVID-19 Patients with Septic Shock	The aim of this study was to determine whether statins reduce the mortality in COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04373232	Southeast University, China	11-Oct-21	30-Sep-23	22-Jul-21	3-Jan-22	Lin Wang Department of Critical Care Medicine, School of Medicine, Southeast University linwang@seu.edu.cn	Lin Wang, MD-PhD linwang@seu.edu.cn 20252323@seu.edu.cn	https://www.clinicaltrials.gov/ct2/show/study/NCT04373232
Efficiency and Safety Evaluation of COVID-19 Inhibitors	The purpose of this study is to evaluate safety, tolerability, and efficacy of COVID-19 inhibitors in hospitalized patients with severe COVID-19 respiratory distress syndrome. (NIH R01-HL138501)	NCT04384979	Qian Biotech, Biopharmaceutical Co., Ltd., Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	Nov-21	Nov-21	29-Mar-22	29-Mar-22	Minghui Shi Qian Biotech shiminghui@qianbiotech.com	Qian Biotech Sanofi Sinovent Sanofi Sinovent Contact: Jingjun, MD, PhD 20252323@seu.edu.cn 20252323@seu.edu.cn 20252323@seu.edu.cn	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Basic Science Mechanism of Action	To understand the cellular and molecular mechanisms of disease severity in hospitalized patients with COVID-19, we conducted a multi-center observational study to determine the role of ACE2 in disease severity in hospitalized patients with COVID-19. (NIH R01-HL138501)	NCT04384979	Direct Biologics, LLC	1-Jul-22	3-Jul-22	28-Apr-22	28-Apr-22	Wenbin Song, MD Direct Biologics wensong@directbiologics.com	Wenbin Song Wenbin.Song@directbiologics.com 800-761-1021	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Industrialized Development of COVID-19 Inhibitors	The primary objective for the industrialized development of COVID-19 inhibitors is to determine the safety and efficacy of the inhibitors in hospitalized patients with COVID-19. (NIH R01-HL138501)	NCT04384979	University of California San Diego	14-Mar-22	25-Feb-26	25-Feb-22	1-Apr-22	Victor Salvendy Department of Molecular Biology and Biotechnology, University of California San Diego victor.salvendy@ucsd.edu	Victor Salvendy victor.salvendy@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Prevention to Prevent Fibrosis in COVID-19 Patients	This is a randomized controlled trial to evaluate the efficacy of a novel COVID-19 inhibitor in preventing the development of fibrosis in COVID-19 patients. (NIH R01-HL138501)	NCT04384979	University of California San Diego	Oct-21	Oct-21	15-Oct-21	27-Feb-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Effect of Early Treatment with Remdesivir in COVID-19 Patients with Septic Shock	This study is a multicenter, prospective, observational study to evaluate the efficacy of early treatment with Remdesivir in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	University of California San Diego	28-Sep-22	19-Aug-23	28-Aug-22	28-Oct-22	Southern medical center Department of Infectious Diseases, University of California San Diego southern.medical@ucsd.edu	Southern medical center southern.medical@ucsd.edu 619-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Efficiency of COVID-19 Inhibitors	The main goal of this study is to evaluate the safety, tolerability, and efficacy of COVID-19 inhibitors in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	University of California San Diego	1-Jul-22	3-Jul-22	27-Jul-22	28-Mar-22	Wenbin Song, MD Direct Biologics wensong@directbiologics.com	Wenbin Song Wenbin.Song@directbiologics.com 800-761-1021	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Protective Effect of Statins in COVID-19 Patients with Septic Shock	The aim of this study was to determine whether statins reduce the mortality in COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Southeast University, China	11-Oct-21	30-Sep-23	22-Jul-21	3-Jan-22	Lin Wang Department of Critical Care Medicine, School of Medicine, Southeast University linwang@seu.edu.cn	Lin Wang, MD-PhD linwang@seu.edu.cn 20252323@seu.edu.cn	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Treatment of COVID-19 Inhibitors	Therefore, this study was intended to evaluate the efficacy of COVID-19 inhibitors in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	18-Sep-22	20-Jul-24	2-Jun-22	19-Apr-22	Hao Zhang, MD Sanofi Sinovent haozhang@sanofisinovent.com	Hao Zhang, MD haozhang@sanofisinovent.com 800-761-1021	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Effect of Two Different Doses of Remdesivir in COVID-19 Patients with Septic Shock	Remdesivir is a proven, potent, oral, antiviral drug that is used to treat COVID-19. This study is a multicenter, prospective, observational study to evaluate the efficacy of two different doses of Remdesivir in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	University of California San Diego	2-Feb-22	28-Apr-23	15-Dec-20	1-Mar-22	Jean-Benoit Meunier Department of Infectious Diseases, University of California San Diego meunier@ucsd.edu	Jean-Benoit Meunier meunier@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Treatment with Ribavirin for COVID-19 Patients with Septic Shock	A randomized, open-label, two-arm, pilot trial of Ribavirin in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	8-Jun-20	Dec-21	4-Dec-20	27-Jul-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Study to Test the Highest Safe Dose of Remdesivir	This study is a multicenter, prospective, observational study to evaluate the safety and efficacy of the highest safe dose of Remdesivir in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	29-Mar-20	28-Jul-23	28-Oct-20	2-Jun-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Impact of Intravenous Ribavirin on COVID-19 Patients with Septic Shock	The purpose of this prospective, observational, controlled trial is to evaluate the efficacy of intravenous Ribavirin on patients hospitalized with COVID-19 respiratory distress syndrome (RDS) due to septic shock. (NIH R01-HL138501)	NCT04384979	University of California San Diego	4-Nov-20	Feb-24	28-Oct-20	18-Aug-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
This Study Evaluates the Safety and Efficacy of Remdesivir in COVID-19 Patients with Septic Shock	This study is a multicenter, prospective, observational study to evaluate the safety and efficacy of Remdesivir in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	7-Jul-20	26-Dec-24	4-Jun-20	30-Mar-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Impact of Ribavirin on COVID-19 Patients with Septic Shock	The purpose of this prospective, observational, controlled trial is to evaluate the efficacy of Ribavirin on patients hospitalized with COVID-19 respiratory distress syndrome (RDS) due to septic shock. (NIH R01-HL138501)	NCT04384979	University of California San Diego	4-Nov-20	Feb-24	28-Oct-20	18-Aug-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
A Study of the COVID-19 Inhibitor Remdesivir in Patients with COVID-19	The study is a prospective, randomized, controlled, parallel, single-blind, phase 2 clinical study of the efficacy and safety of Remdesivir in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	29-Mar-20	Dec-21	28-Mar-20	24-Feb-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Evaluating Remdesivir for Treatment of COVID-19 Patients with Septic Shock	The study is designed to evaluate the safety, tolerability, and effectiveness of higher doses of Remdesivir in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	1-Oct-22	1-Mar-25	28-Apr-20	7-Feb-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Safety and Preliminary Efficacy of Remdesivir in COVID-19 Patients with Septic Shock	This phase 1b, randomized, placebo-controlled, double-blind, parallel-group study will assess the safety and preliminary efficacy of Remdesivir in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	14-Sep-19	Jun-23	26-Jul-19	4-Aug-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Inhibitor of ACE2 Inhibition in COVID-19 Patients with Septic Shock	The aim of this experimental medicine study is to assess the effect of using the novel ACE2 inhibitor, Losartan, in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	University of California San Diego	14-Jan-23	15-Mar-24	25-Oct-22	15-Oct-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Phase 2a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Remdesivir in COVID-19 Patients with Septic Shock	This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Remdesivir in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	1-Sep-21	1-Sep-23	11-Jul-21	28-Aug-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Phase 2a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Remdesivir in COVID-19 Patients with Septic Shock	This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Remdesivir in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	1-Sep-21	1-Sep-23	11-Jul-21	28-Aug-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979
Phase 2a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Remdesivir in COVID-19 Patients with Septic Shock	This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Remdesivir in hospitalized COVID-19 patients with septic shock. (NIH R01-HL138501)	NCT04384979	Sanofi Sinovent Sanofi Sinovent Sanofi Sinovent	1-Sep-21	1-Sep-23	11-Jul-21	28-Aug-22	Geoffrey Yip Department of Molecular Biology and Biotechnology, University of California San Diego geoffrey.yip@ucsd.edu	Geoffrey Yip geoffrey.yip@ucsd.edu 760-534-9000	https://www.clinicaltrials.gov/ct2/show/study/NCT04384979

Study Title	Lead PI	Site	Start	End	Phase	Status	Contact	Link
Treatment of COVID-19 with ivermectin (IPIV-19)	MCT015116	University of Minnesota	21-Oct-19	10-Dec-23	4-Oct-19	2-Oct-20	Principal Investigator: Thomas A. Van Dyke Contact: Amy McKeown, MDA, MSH202425@tc.umn.edu Contact: Melissa A. Balby, MSH202426@tc.umn.edu University of Minnesota	https://clinicaltrials.gov/ct2/show/study/NCT04151116
A Non-Binding Study to Assess the Safety, Tolerability and Feasibility of	MCT036882	Angen Pharma Limited	4-Mar-20	31-Aug-24	28-May-19	22-Feb-20	Study Director: Steve Clark, Poligon Group Ltd Contact: Investor Affairs, MSH204910 137730@angpharma.com	https://clinicaltrials.gov/ct2/show/study/NCT036882
Intact Domain Alpha to Reduce Respiratory Failure After Severe Trauma (ALPHA-19001)	MCT036882	University Hospital, Strasbourg, France	14-Feb-18	1-Oct-24	15-Oct-17	9-Jul-22	Contact: Louise POTIERE, MD-133 1603105@unistra.fr	https://clinicaltrials.gov/ct2/show/study/NCT036882
Improvement of Pulmonary Mechanics After Mechanical Ventilation in Severe COVID-19 Patients (IMPROVING-2)	MCT036888	First Affiliated Hospital Xi'an Jiaotong University	20-Apr-21	10-Dec-26	20-Apr-21	20-Apr-21	Study Chair: Tao Shi, MD PhD Contact: Tao Shi, PhD 202104220000@xjtu.edu.cn	https://clinicaltrials.gov/ct2/show/study/NCT036888
A Study to Assess the Safety and Efficacy of CD301 in Patients With Acute Respiratory Distress Syndrome (ARDS) (CD301-02)	MCT040001	Sponsor: Grand Medical Inc, Collaborator: Grand Pharmaceutical (Shanghai, Inc)	28-Jul-21	Dec-22	18-Aug-21	December 21, 2021	Jane Peng, PhD-14 6034468@grandpharma.com	https://clinicaltrials.gov/ct2/show/study/NCT040001
Efficacy of Crossover as an Add-On to Nebulized Severe ARDS in COVID-19 (MICRO-2)	MCT040780	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Pizzardi e S. Maria Cecilia Hospital, Università di Bologna	3-Sep-21	Dec-23	17-Jul-21	16-May-23	Principal Investigator: Marco Vignati, MD PhD Coordinator: Riccardo Magagnoli, MD PhD CROF018@unibo.it	https://clinicaltrials.gov/ct2/show/study/NCT040780
Protective Effect of Inhaled Saline with PulmoShield in Severe COVID-19 Patients (PULMO-2)	MCT040780	Safford University, Ohio	11-Oct-21	8-Oct-23	22-Jul-21	2-Jun-22	Study Chair: Ting Ting, PhD Coordinator: Ting Ting, MD PhD 620374520@stjohnsb.edu	https://clinicaltrials.gov/ct2/show/study/NCT040780
Treatment of ARDS With Inhaled Saline (INSAL)	MCT040887	Yokohama National University Hospital, Japan	18-Apr-22	31-Jul-24	2-Jun-21	6-Apr-22	Principal Investigator: Masahiro Hasegawa, MD PhD Contact: Masahiro Hasegawa, MD PhD hasegawa@yokohama-n.ac.jp	https://clinicaltrials.gov/ct2/show/study/NCT040887
Efficacy of Two Subsequent Doses of Inhaled Saline on Mortality in Patients With ARDS and COVID-19 (INSAL-2)	MCT040955	Bris University Hospital, Newcastle University, Newcastle General Hospital, Newcastle upon Tyne, General University Hospital, St Anne's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Study to Assess the Effect of Inhaled Saline on Mortality in Patients With ARDS and COVID-19 (INSAL-3)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Treatment With Proliferation of COVID-19 Related Severe ARDS	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Study to Assess the Effect of Inhaled Saline on Mortality in Patients With ARDS and COVID-19 (INSAL-4)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Impact of Intravenous Saline on Mortality in Patients With ARDS and COVID-19 (INSAL-5)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Study to Assess the Effect of Inhaled Saline on Mortality in Patients With ARDS and COVID-19 (INSAL-6)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-7)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Efficacy of Inhaled Saline in Patients With ARDS and COVID-19 (INSAL-8)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-9)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-10)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-11)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-12)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-13)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-14)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-15)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-16)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-17)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-18)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-19)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955
Effectiveness of Nebulized Saline in Patients With ARDS and COVID-19 (INSAL-20)	MCT040955	St Anna's University Hospital, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne, Newcastle University, Newcastle upon Tyne	2-Feb-21	16-Mar-23	12-Dec-20	16-Mar-23	Contact: Jon Mervin, MD, PhD G04040222023@newcastle.ac.uk Contact: Ian Galloway, MD, PhD G04040222023@newcastle.ac.uk	https://clinicaltrials.gov/ct2/show/study/NCT040955

Study Title	Abstract	Phase	Start Date	End Date	Status	Lead Investigator	Contact	Link
ACTN 01: Therapeutic for Severe to Very Severe COVID-19 (RESCUE)	This study looks at the safety and effectiveness of remdesivir in COVID-19 patients who have been hospitalized with the infection and who have not been treated with another drug. It will also look at whether patients who are treated with remdesivir will have a shorter hospital stay and/or a shorter time to recovery than those who are not treated with remdesivir.	Phase 3	20-Apr-21	1-Nov-21	14-Apr-21	19-Dec-21	7	View Full Text
WHO 14: In the Treatment of SARS-CoV-2 Infection by Assessing the Effect on the Proportion of Patients Who are Severe (WHO 14)	To assess the efficacy of WHO 14 in the treatment of SARS-CoV-2 infection by assessing its effect on the proportion of patients who are severe (WHO 14) in the study (WHO 14).	Phase 3	18-May-21	6-Jul-21	13-Apr-21	26-Aug-21	7	View Full Text
Safety and Efficacy of GSK3368793 in Respiratory Distress Due to COVID-19	This trial will study the use of GSK3368793 given as an intravenous infusion to patients with respiratory distress due to infection with COVID-19.	Phase 3	27-Jul-21	Mar-22	2-Mar-21	30-Jan-22	7	View Full Text
Sanctuary to Prevent Reintroduction of SARS-CoV-2 Infection in Patients With Severe Respiratory Failure and Oxygen Requirements (SARF-2)	This is a phase 3 study designed to evaluate whether the administration of gaseous oxygen via a non-invasive respiratory system (NIV) compared to high-flow nasal cannula oxygen (HFNC) in intubated patients with severe respiratory failure. The primary endpoint is the proportion of patients who are discharged from the intensive care unit (ICU) alive and without the need for re-intubation.	Phase 3	29-Jun-21	21-Aug-21	12-Jun-21	19-Jul-21	7	View Full Text
Empirical Studies on COVID-19 Infection in Patients With Severe Respiratory Failure From Immunological Etiology (EMPIRE)	The main objective of this study is to reduce the 90-day mortality in immunocompetent patients with acute respiratory failure (ARF) due to COVID-19. The intervention will evaluate the impact of a combination of 1) a 14-day course of intravenous immunoglobulin (IVIg) and 2) a 14-day course of corticosteroids.	Phase 3	21-Oct-20	21-Dec-20	23-Dec-20	23-Dec-20	7	View Full Text
Study of Melatonin in Moderate and Severe Hospitalized COVID-19 Patients	This is a 2-part, Phase 2b, multicenter, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral melatonin (MEL) in moderate and severe hospitalized COVID-19 patients compared to placebo.	Phase 2b	7-Oct-20	Dec-21	27-Oct-20	26-Apr-21	7	View Full Text
Efficacy of SARS-CoV-2 Infection in Patients With Severe Respiratory Failure Caused by Infection (SARF-1)	This is a multicenter, randomized, controlled, open-label clinical trial testing immunotherapy in mechanically ventilated adult patients with mechanical ventilation (MV) requiring ARF. Patients will be randomized to either receive immunotherapy or standard of care.	Phase 3	4-Jul-21	30-Dec-21	09-Sep-20	23-Mar-21	7	View Full Text
WHO 19: Outpatient in Patients With Severe Respiratory Failure Caused by Infection (WHO 19)	This is a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of WHO 19 (WHO 19) in patients with severe respiratory failure (ARF) due to COVID-19. The primary endpoint is the proportion of patients who are discharged from the ICU alive and without the need for re-intubation.	Phase 3	11-Nov-20	30-Nov-20	22-Jul-20	3-Aug-21	7	View Full Text
Universal Acid-Base Therapy for Healthy Older Adults (ACTN 02)	This protocol will study the safety and efficacy of a novel universal buffer (sodium bicarbonate) in patients with severe respiratory failure (ARF) due to COVID-19. The primary endpoint is the proportion of patients who are discharged from the ICU alive and without the need for re-intubation.	Phase 3	12-Jul-21	10-Dec-21	20-Jun-20	21-Aug-21	7	View Full Text
Efficacy and Safety of Tocilizumab in Patients Hospitalized for Severe COVID-19 Infection Requiring Supplemental Oxygen (TICU)	The purpose of this study is to evaluate the effect of tocilizumab in adult in-hospital patients with severe COVID-19 infection requiring supplemental oxygen on the proportion of patients who are discharged from the ICU alive.	Phase 3	10-Dec-20	9-Feb-21	22-Nov-20	30-Dec-20	7	View Full Text
A Study of Micro Biome in Hospitalized Patients With Severe Respiratory Failure Due to COVID-19	This study will evaluate whether administration of tocilizumab to adult in-hospital patients with severe COVID-19 infection requiring supplemental oxygen on the proportion of patients who are discharged from the ICU alive.	Phase 3	8-Feb-21	31-Jul-21	25-Feb-21	20-Dec-21	7	View Full Text